Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis

por Verstovsek, S, Atallah, E, Mascarenhas, J, Sun, H, Montgomery, M, Gupta, V, Mesa, R, Gotlib, J
Publicado 2016

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis

por Verstovsek, S, Talpaz, M, Ritchie, E, Wadleigh, M, Odenike, O, Jamieson, C, Stein, B, Uno, T, Mesa, R A
Publicado 2017

P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES

por Harrison, C., Kiladjian, J.-J., Vannucchi, A. M., Mesa, R. A., Scherber, R. M., Hamer-Maansson, J., Verstovsek, S.
Publicado 2022

P1062: A REAL-WORLD EVALUATION OF THE ASSOCIATION BETWEEN ELEVATED BLOOD COUNTS AND THROMBOTIC EVENTS IN POLYCYTHEMIA VERA: AN ANALYSIS OF DATA FROM THE REVEAL STUDY

por Gerds, A. T., Mesa, R., Burke, J. M., Grunwald, M. R., Scherber, R., Yu, J., Hamer-Maansson, J., Oh, S. T.
Publicado 2022

Evaluation of Patient and Staff Safety Through Continuous Delivery of Radiation Therapy During COVID-19 Pandemic

por Asper, J., Viles, J., Fakhreddine, M., Wagner, T.D., Mesa, R., Ramirez, C., Sickora, C., Nordwick, W., Bonnen, M.D.
Publicado 2021

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA

por Harrison, C., Bose, P., Mesa, R., Gerds, A., Oh, S., Kiladjian, J.-J., García-Gutierrez, V., Vannucchi, A., Scheid, C., Sobas, M., Verstovsek, S., Buckley, S., Roman-Torres, K., Mascarenhas, J.
Publicado 2022

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS

por Kiladjian, J.-J., Tefferi, A., Passamonti, F., Vannucchi, A., Talpaz, M., Cervantes, F., Harrison, C. N., Mesa, R. A., Mascarenhas, J., Schaap, N., Verstovsek, S., Devos, T., Rose, S., Zhang, J., Sy, O., Pardanani, A.
Publicado 2022

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS

por Vannucchi, A., Pemmaraju, N., Scott, B., Savona, M., Oh, S., Palandri, F., Al-Ali, H. K., Sobas, M., McMullin, M. F., Gupta, V., Yacoub, A., Mesa, R., Buckley, S., Roman-Torres, K., Verstovsek, S., Harrison, C.
Publicado 2022

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

por Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, Reiser, D, Zhong, J, Gale, R P
Publicado 2017

P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREAT...

por Gupta, V., Yacoub, A., Verstovsek, S., Mesa, R. A., Harrison, C. N., Barosi, G., Kiladjian, J.-J., Deeg, H. J., Fazal, S., Foltz, L., Mattison, R. J., Miller, C. B., Parameswaran, V., Hernandez, C., Zhang, J., Talpaz, M.
Publicado 2022

Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

por Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, McMullin, M F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, Reiser, D, Zhong, J, Gale, R P
Publicado 2017

P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM]

por Vannucchi, A., Mesa, R., Gerds, A., Al-Ali, H. K., Lavie, D., Kuykendall, A., Grosicki, S., Iurlo, A., Goh, Y. T., Lazaroiu, M., Egyed, M., Fox, M. L., McLornan, D., Perkins, A., Yoon, S.-S., Gupta, V., Kiladjian, J.-J., Donahue, R., Kawashima, J., Verstovsek, S.
Publicado 2022

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYEL...

por Harrison, C., Rampal, R. K., Gupta, V., Verstovsek, S., Talpaz, M., Kiladjian, J.-J., Mesa, R., Kuykendall, A., Vannucchi, A., Palandri, F., Grosicki, S., Devos, T., Jourdan, E., Wondergem, M. J., Al-Ali, H. K., Buxhofer-Ausch, V., Alvarez-Larrán, A., Akhani, S., Muñoz-Carerras, R., Sheykin, Y., Colak, G., Harris, M., Mascarenhas, J.
Publicado 2022

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies

por Bogenberger, J M, Kornblau, S M, Pierceall, W E, Lena, R, Chow, D, Shi, C-X, Mantei, J, Ahmann, G, Gonzales, I M, Choudhary, A, Valdez, R, Camoriano, J, Fauble, V, Tiedemann, R E, Qiu, Y H, Coombes, K R, Cardone, M, Braggio, E, Yin, H, Azorsa, D O, Mesa, R A, Stewart, A K, Tibes, R
Publicado 2014

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

por Mascarenhas, J, Kosiorek, H, Prchal, J, Yacoub, A, Berenzon, D, Baer, MR, Ritchie, E, Silver, RT, Kessler, C, Winton, E, Finazzi, MC, Rambaldi, A, Vannucchi, AM, Leibowitz, D, Rondelli, D, Arcasoy, MO, Catchatourian, R, Vadakara, J, Rosti, V, Hexner, E, Kremyanskaya, M, Sandy, L, Tripodi, J, Najfeld, V, Farnoud, N, Salama, ME, Weinberg, RS, Rampal, R, Goldberg, JD, Mesa, R, Dueck, AC, Hoffman, R
Publicado 2019

P1051: A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS

por Gill, H., Yacoub, A., Pettit, K., Bradley, T., Gerds, A., Tatarczuch, M., Shortt, J., Curtin, N., Rossetti, J., Burbury, K., Mead, A., Göthert, J., Koschmieder, S., Jones, A., Peppe, J., Dias, J., Natsoulis, G., McClure, T., Kleppe, M., Hong, W.-J., Stevenson, W., Ewing, J., Chacko, J., Rumi, E., Halpern, A., Palandri, F., Vianelli, N., Passamonti, F., Mesa, R., Marchetti, M., Harrison, C., Vannucchi, A., Watts, J., Ross, D., Talpaz, M., Rienhoff, H.
Publicado 2022

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

por Grivas, P., Khaki, A.R., Wise-Draper, T.M., French, B., Hennessy, C., Hsu, C.-Y., Shyr, Y., Li, X., Choueiri, T.K., Painter, C.A., Peters, S., Rini, B.I., Thompson, M.A., Mishra, S., Rivera, D.R., Acoba, J.D., Abidi, M.Z., Bakouny, Z., Bashir, B., Bekaii-Saab, T., Berg, S., Bernicker, E.H., Bilen, M.A., Bindal, P., Bishnoi, R., Bouganim, N., Bowles, D.W., Cabal, A., Caimi, P.F., Chism, D.D., Crowell, J., Curran, C., Desai, A., Dixon, B., Doroshow, D.B., Durbin, E.B., Elkrief, A., Farmakiotis, D., Fazio, A., Fecher, L.A., Flora, D.B., Friese, C.R., Fu, J., Gadgeel, S.M., Galsky, M.D., Gill, D.M., Glover, M.J., Goyal, S., Grover, P., Gulati, S., Gupta, S., Halabi, S., Halfdanarson, T.R., Halmos, B., Hausrath, D.J., Hawley, J.E., Hsu, E., Huynh-Le, M., Hwang, C., Jani, C., Jayaraj, A., Johnson, D.B., Kasi, A., Khan, H., Koshkin, V.S., Kuderer, N.M., Kwon, D.H., Lammers, P.E., Li, A., Loaiza-Bonilla, A., Low, C.A., Lustberg, M.B., Lyman, G.H., McKay, R.R., McNair, C., Menon, H., Mesa, R.A., Mico, V., Mundt, D., Nagaraj, G., Nakasone, E.S., Nakayama, J., Nizam, A., Nock, N.L., Park, C., Patel, J.M., Patel, K.G., Peddi, P., Pennell, N.A., Piper-Vallillo, A.J., Puc, M., Ravindranathan, D., Reeves, M.E., Reuben, D.Y., Rosenstein, L., Rosovsky, R.P., Rubinstein, S.M., Salazar, M., Schmidt, A.L., Schwartz, G.K., Shah, M.R., Shah, S.A., Shah, C., Shaya, J.A., Singh, S.R.K., Smits, M., Stockerl-Goldstein, K.E., Stover, D.G., Streckfuss, M., Subbiah, S., Tachiki, L., Tadesse, E., Thakkar, A., Tucker, M.D., Verma, A.K., Vinh, D.C., Weiss, M., Wu, J.T., Wulff-Burchfield, E., Xie, Z., Yu, P.P., Zhang, T., Zhou, A.Y., Zhu, H., Zubiri, L., Shah, D.P., Warner, J.L., Lopes, GdL.
Publicado 2021